This is part one of an FDA Week Special Report on patient engagement in the drug development process. Part one focus on the methods FDA and other stakeholders are taking to better engage patients. Part two looks at the regulatory and technological hurdles involved in bringing real-world patient data into the drug development process. As policymakers and industry work to achieve the promise of 21st century cures, the barriers between pharmaceutical companies and the consumers they serve...